Bibliography--Neural Sensitization: The Medical Key To Treatment
1 P Gregersen, “Chronic Toxic Encephalopathy in Solvent-exposed Painters in Denmark 1976-1980: Clinical cases and social consequences after a 5-year follow-up”, Am J of Ind Med , 11: 399-417, 1987.
2 JE Haley etal., “Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat”, Brain Res 518:218-226, 1990.
3 M Lafon-Cazal etal., “Nitric oxide, superoxide and peroxynitrite: putative mediation of NMDA-induced cell death in cerebellar cells”, Neuropharmacology 32:1259-1266, 1999.
4 IJ Reynolds and TG Hastings, “Glutamate produces production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation”, J. Neurosci 15:3318-3327, 1995.
5 R Delfino, etal, “Personal and ambient air pollution is associated with increased exhaled nitric oxide in children with asthma”, Env Health Persp, 114: 1736-1743, 2006.
6 JS Beckman, “The double edged role of nitric oxide in brain function and superoxide-mediated injury”, J.Dev Physiol 15:53-59, 1991.
7 M Lafon-Cazal etal., “NMDA-dependent superoxide production and neurotoxicity”, Nature 364:535-537,
1993.
8 JT Coyle and P Puttfarken, “Oxidative stress, glutamate and neuro generative disorders”, Science 262:689-695, 1993.
9 AY Sun YM Chen, “Oxidative stress and neurodegenerative disorders”, J Biomed Sci, 5: 401-14, 1998.
10 A Doble, “NMDA and neurodegenerative conditions (reviews)”, Pharmacol Ther 81:163-221, 1999.
11 VL Dawson and TM Dawson, “Nitric oxide neurotoxicity”, J Chem Neuroanat 10:179-190, 1996.
12 BC Albenzi, “Models of brain injury and alterations in synaptic neuroplasticity”, J. Neurosci Res 65:279-283, 2001.
13 WG Mayhan, “Nitric oxide donor-induced increase in permeability of the blood-brain barrier”, Brain Res 866;101-108, 2000.
14 OG Khatsenko etal., “Nitric oxide is a mediator of the decrease in cytochrome p450-dependent metabolism caused by immunostimulants”, Proc Nat Acad Sci USA 90:11147-11151, 1993.
15 F Therese, etal, “Exhaled nitric oxide in children with asthma and short-term PM2.5 exposure in Seattle”, Environ Health Perspect 113: 1791-1794, 2005.
16 JS Beckman and JP Crow, “Pathologic implications of nitric oxide, superoxide and peroxynitrite formation”, Biochem Soc Trans 21:330-333, 1993.
17 WA Pryor and GL Squadrito, “The chemistry of peroxynitrite: a product of the reaction of nitric oxide and superoxide”, Am J. Physiol 268:L699-L722, 1995.
18 A Novelli etal., “Glutamate becomes neurotoxic via the NMDA receptor when intracellular energy levels become reduced”, Brain Res 451:205-212, 1988.
19 JB Schultz etal., “The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases”, Mol Cell Biochem 174:171-184, 1997.
20 M Hayakawa etal “Age-related oxygen damage and mutations in mitochondrial DNA in human hearts”, Biochem Biophys Res Commun 189: 979-985, 1992.
21 G Ziem, “Profile of patients with chemical injury and sensitivity”, Int J Toxicol 18:401-409, 1999.
22 F Ozguner, etal, “Mobile phone-induced myocardial oxidative stress: Protection by a novel antioxidant agent caffeic acid phenethyl ester:, Toxicol and Indus Health 21: 223-230, 2005.
23 WD Willis, Role of neurotransmitters in sensitization of pain responses,” Ann NY Acad Sci 933;175-184, 2001.
24 A Wu and Y Lin, Brain Res Mol Brain Res 110: 147, 2003.
25 SB McMahon etal., “Central excitability triggered by noxious inputs”, Current Opin Neurobiol 3:602-610, 1993.
26 A Beiruth etal, “Spinal and supraspinal antinociceptive action of dipyrone in formalin, capsaicin and glutamate tests. Study of the mechanism of action, “Env J Pharmacol 345: 233-245, 1998.
27 E Palazzo etal, “Interaction between vanilloid and glutamate receptors in the central modulation of nociception:, Env J Pharmacol 439- 69-75, 2002.
28 H Kimata etal, “Effect of exposure to volatile organic compounds on plasma levels of neuropeptides, nerve growth factor and histamine in patients with chemical sensitivity”, Int J Hyg Environ Health 159-63, 2004.
29 WJ Meggs, “The toxic induction of asthma and rhinitis”, Clinical Toxicol 32: 487-501, 1994.
30 TR Garbe and H Yukama, “Common solvent toxicity: auto oxidation of respiratory redox-cyclers enforced by membrane derangement”, Z Natur forsch 56:483-491, 2001.
31 CJ Mattia etal., “Toluene-induced oxidative stress in several brain regions and other organs”, Mol Chem Neurophysiol 18:313-328, 1993.
32 JS Bechman and JP Crow, “Pathological implications of nitric oxide, superoxide and peroxynitrite function”, Biochem Soc Trans 21: 330-334, 1993.
33 WA Pryor and G Squadrito, “The chemistry of peroxynitrite: a product of the reaction of nitric oxide and superoxide”, Am J Physiol 268:L 699-L722, 1995.
34 SR Thom etal “Neuronal nitric oxide synthase and n-methyl-d-aspartate neurons in experimental carbon monoxide poisoning”, Toxicol Applied Pharmacol 194: 280-295, 2004.
35 RE Lenga, Ed., Sigma-Aldrich Library of Chemical Safety Data. Sigma-Aldrich Corp, 1988.
36 GE Ziem, “Evaluation and Treatment of Patients with Chemical Injury and Sensitivity” Invited presentation at Aug 13-15, 2001 Conference sponsored by the National Institute of Environmental Health Sciences.
37 F Therese, etal, “Exhaled nitric oxide in children with asthma and short-term PM2,5 exposure in Seattle”, Env Health Persp 113: 1791-1794, 2005.
38 IN Roehm etal, “The influence of vitamin E on the lung fatty acids of rats exposed to ozone”, Archiv Environ Health 24: 237-242, 1972.
39 H Sprince etal, “Comparison of protection by L-ascorbic acid, L-cysteine, formaldehyde toxicity”, agents and actions 9: 407-414, 1979.
40 GA Pascoe etal, “A role of vitamin E in protection against cell injury, Env J Biochem 166: 241-247, 1987.
41 G Ziem, “Endocrine Changes in Patients with Chronic Illness Following Chemical Overexposure”, Invited presentation at Conference on Chemical Injury, Fairfax, VA, October 3, 2003.
42 G Ziem, “Medical evaluation and treatment of patients with chemical injury and sensitivity”, Invited presentation at Aug 13-15, 2001 Conference sponsored by the National Institute of Environmental Health Sciences.
43 D Z van Asselt etal., “Nasal absorption of hydroxycobalamine in healthy elderly adults”, Brit J Pharmacol 45: 83-86, 1998.
44 W B Slot, etal., “Normalization of plasma vitamin B12 by intranasal hydroxycobalamine in vitamin B12 deficient patients”, Gastroenterology 113: 430-433, 1997.
45 P H van der Kuy etal., “Hydroxycobalamine, a nitric oxide scavenger in the prophylaxis of migraine”, Cephalgia 22: 513-519, 2002.
46 O Stanger, M Weger, “Interactions of homocysteine, nitric oxide, folate and radicals in the progressively damaged epithelium”, Clin Chem Lab Med 41: 1444-1454, 2003.
47 CD Klassen etal, Editors, Casarett and Doulls Toxicology: The Basic Science of Poisons, McGraw Hill, New York, NY, 2001.
48 R Buhl, etal. Oxidant-protease interaction in the lung. Prospects for anti oxidant therapy. Chest 110:267S-272S, 1996
49 C Bishop etal “A pilot study of the effect of inhaled reduced glutathione on the clinical status of patients with cystic fibrosis”, Chest 127: 308-317, 2005.
50 Testa B, Mesolella M, Testa D. Glutathione in the upper respiratory tract. Ann Otol Rhinol Laryngol 1995;101:117-9.
51 Principals of Neurotoxicity Risk Assessment, US EPA, Fed Reg Aug 17, 1994.
52 S Oja etal, Modulation of glutamate receptor functions by glutathione” Neurochemistry International 37: 299-306, 2000.
53 H Sprince, etal, “Comparison of protection by L-ascorbic acid, L-cysteine, and adrenergic-blocking agents against acetaldehyde, acrolein, and formaldehyde toxicity: implications in smoking”. Agents and Actions, 9/4: 407-414, 1979.
54 LJ Machlin and A Bendich “Free radical damage: protective role of antioxidant nutrients”, FASEB J 6: 441-445, 1987.
55 T Konrad etal, “Alpha-lipoic acid decreases serum lactate and pyruate and improves glucose effectiveness in lean and obese patients with type 2 diabetes”, Diabetes Care 22: 280-287, 1999.
56 D Ziegler etal, Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials”, Exp Clin Endocrinol Diabetes 107: 421-430, 1999.
57 A Smith etal, “Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress”, Corr Med Chem 11: 1135-1146, 2004.
58 H Moini etal., “Antioxidant and proxidant activities of alpha lipoic acid and dihydrolipoic acid”, Toxocol Appl Pharm 182: 84-90, 2002.
59 A Blast, G Haenen, “Interplay between lipoic acid and glutathione in microsomal lipid peroxidation”, Biochem Biophys Acta 963: 558-561, 1988.
60 P Porras etal., “Glutaredioxins catalyze the reduction of glutathione by dihydrolipomide with high efficiency”, Biochem Biophys Res
Commun 295: 1046-1051, 2002.
61 S Hustad etal, “Riboflavin, flavin mononucleotide, flavin adenine dinucleotide in human plasma and erythrocytes at baseline and after low-dose riboflavin supplementation”, Clin Chem 48; 1571-1577, 2002.
62 A Prentice, C Bates, “A biochemical evaluation of the erythrocyte glutathione reductase (EC1.6.4.2) test for riboflavin status. Dose response relationships in chronic marginal deficiency”, Brit J Nutr 45: 53-65, 1981.
63 J Schoenen etal, “Effectiveness of high-dose riboflavin in migraine prophylaxis”, Dept of Neurology, University of Liege, Belgium.
64 Casarett and Doull's Toxicology, MacMillan, NY, 3rd Edition, 2001.
65 M Jones, “Chronic neuropathic pain: pharmacological in the new millennium”, Internat J Pharmaceutical Compounding, Jan-Feb 2000.
66 S Christen etal,“Gamma-tocopherol traps mutagenic electrophiles such as NOx and complements alpha-tocopherol: Physiologic implications” Proc Natl Acad Sci 94: 3217-3222, 1997.
67 K Wagner etal, “Gamma-tocopherol-an underestimated vitamin” J Nutr 122: 2440-2446, 1992.
68 E Giovannucci, Y-Tocopherol: a new player in prostate cancer prevention” J Natl Cancer Inst, 92: 1966-1967, 2000.
69 GA Pascoe, etal, “A role in vitamin E in protection against cell injury, maintenance of intracellular glutathione precursors and biosynthesis”, Eur J Biochem 166: 241-247, 1987.
70 JN Roehm, etal, Antioxidants vs lung disease”, Arch Intern Med 128: 88-93, 1971.
71 BL Fletcher and AL Tappel, “Protective effects of dietary tocopherol in rats exposed to toxic levels of ozone and nitrogen dioxide.” Env Research 6: 165-175, 1973.
72 J Feher etal, “Oxidative stress in the liver and biliary tract diseases”, Scand J Gastroenterol 228: S38-S46, 1998.
73 F Cohen-Boulakia et al, “In vivo sequential study of skeletal muscle capillary fragility in diabetic rats: effects of anthocyanosides”. Metabolism 49: 880-885, 2000.
74 M Perossini etal, “Diabetic and hypertensive retinopathy therapy with vaccinium myrtillus anthocyanosides: a double blind, placebo-controlled trial”, Ann Ofthalm Clin Ocul 113: 1173-1190, 1987.
75 JO Moskaug, etal, “Dietary Polyphenols and Health: Proceedings of the 1st International Conference on Polyphenols and Health”, Am J Clin Nutr 81: 277S-283S, 2005.
76 N Kocak-Toker, etal, “Peroxynitrite induced decrease in Na+, K+-ATPase activity is restored by taurine.” World Journal of Gastroenterology. 11: 3554-3557, 2005.
77 D Bagchi etal, “Oxygen free radical scavenging abilities of vitamins C, E and a grape seed proanthocyanidin in vitro”, Free Radical Biol Med 16: 845-50, 1994.
78 T Yokozawa etal, “(-)-Epigallocatechin 3-0-gallate ameliorates the damage related to peroxynitrite production by mechanisms distinct from other free radical inhibitors”, Xenobiotica 33: 913-25, 2003.
79 A Higuchi etal, “Inhibitory activity of epigallocatechin gallate (EGCg) in paraquat-induced microsomal lipid peroxidation”, Int Immunopharmacol 2: 849-55, 2002.
80 E Alvarez etal, “Effect of (-)-epigallocatechin-3-gallate on respiratory burst of rat macrophages”, Biosci Biotechnol Biochem 63: 1621-1623, 1999.
81 Food Research Institute, Mitsui Norin Co Ltd, “Radical scavenging activity of tea catechins and their related compounds”, J Agri Food Chem 47: 425-431, 1999.
82 G Muzes etal, “Effect of the bioflavinoid silimarin on the in vitro activity and expression of superoxide dismutase (SOD) enzyme”, Tokai J Exp Clin Med 15: 129-134, 1990.
83 J Feher etal, “In vivo effect of free radical scavenger hepatoprotective agents on superoxide dismutase activity in patients”. Tokai J Exp Clin Med, 15: 129-134, 1990.
84 A Eldrissi, E Trenkner, “Taurine as a modulator of excitatory and inhibitory neurotransmission”, Neurochem Res 29: 189-197, 2004.
85 SA Sulaiman etal, “Kinetic studies on the inhibition of GABA-T by gamma-vinyl GABA and taurine”, J Enzyme Inhib Med Chem 18:297-301, 2003.
86 N del Olmo etal, “Taurine activates GABA (A) but not GABA (B) receptors in rat hippocampal CA1 area”, Brain Res 864: 298-307.
87 K Kaneda etal., “The effects of B vitamins on glutamate-induced neurotoxicity in retinal cultures”, Env J Pharmacol 322:259-264, 1997.
88 H Wang etal., “ Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy”, Arch Dis Child 90: 512-515, 2005.
89 J Liu etal “Comparison of the effects of L-carnitine and acetyl-L-carnitine”, Ann NY Acad Sci 1033: 117-131, 2004.
90 A Guyton and J Hall, Editors, Textbook of Medical Physiology, WB Saunders Co., Philadelphia, PA.
91 L Packer etal, “Neuroprotection by the metabolic antioxidant alpha-lipoic acid”, Free Radio Biol Med 22: 359-378, 1997.
92 M Trujillo etal, “Peroxynitrite-derived carbonate and nitrogen dioxide radicals readily react with lipoic acid and dihydrolipoic acid”, Free Radic Biol Med 39: 279-288, 2005.
93 MC Linder, editor, Nutritional Biochemistry and Metabolism, Appleton and Lange, 1991.
94 RK Murray etal, editors, Harper’s Biochemistry, Appleton and Lange, 1993.
Back to: New Treatment for Chemical Injury and Chemical Sensitivity
Home
|
